Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

New trials and results in systemic treatment of HCC.

Reig M, da Fonseca LG, Faivre S.

J Hepatol. 2018 Aug;69(2):525-533. doi: 10.1016/j.jhep.2018.03.028. Epub 2018 Apr 11. Review.

PMID:
29653122
2.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
3.

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.

Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S.

Clin Cancer Res. 2018 Jun 1;24(11):2505-2516. doi: 10.1158/1078-0432.CCR-17-2644. Epub 2018 Feb 28.

PMID:
29490986
4.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW.

Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21.

5.

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

Szturz P, Budíková M, Vermorken JB, Horová I, Gál B, Raymond E, de Gramont A, Faivre S.

Oral Oncol. 2017 Nov;74:68-76. doi: 10.1016/j.oraloncology.2017.09.009. Epub 2017 Sep 27. Review.

PMID:
29103754
6.

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S.

Hepatology. 2018 Mar;67(3):1132-1149. doi: 10.1002/hep.29496. Epub 2018 Feb 1. Review.

7.

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers.

Escudier B, Faivre S, Van Cutsem E, Germann N, Pouget JC, Plummer R, Vergote I, Thistlethwaite F, Bjarnason GA, Jones R, Mackay H, Edeline J, Fartoux L, Hirte H, Oza A.

Target Oncol. 2017 Oct;12(5):655-661. doi: 10.1007/s11523-017-0525-2.

PMID:
28798986
8.

Characteristics of socially withdrawn youth in France: A retrospective study.

Chauliac N, Couillet A, Faivre S, Brochard N, Terra JL.

Int J Soc Psychiatry. 2017 Jun;63(4):339-344. doi: 10.1177/0020764017704474. Epub 2017 Apr 26.

PMID:
28446040
9.

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S.

Crit Rev Oncol Hematol. 2017 Mar;111:39-51. doi: 10.1016/j.critrevonc.2017.01.004. Epub 2017 Jan 12. Review.

PMID:
28259294
10.

Novel TGF-β inhibitors ready for prime time in onco-immunology.

de Gramont A, Faivre S, Raymond E.

Oncoimmunology. 2016 Dec 7;6(1):e1257453. doi: 10.1080/2162402X.2016.1257453. eCollection 2017. Review.

11.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L.

Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26.

PMID:
28131786
12.

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.

Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E.

Int J Nanomedicine. 2016 Nov 21;11:6207-6216. eCollection 2016.

13.

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.

Bouattour M, Soubrane O, de Gramont A, Faivre S.

Trials. 2016 Nov 25;17(1):563.

14.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885
15.

Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.

Cauchy F, Mebarki M, Leporq B, Laouirem S, Albuquerque M, Lambert S, Bourgoin P, Soubrane O, Van Beers BE, Faivre S, Bedossa P, Paradis V.

Clin Sci (Lond). 2017 Jan 1;131(1):27-36. Epub 2016 Nov 1.

PMID:
27803295
16.

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

Szturz P, Faivre S.

Oral Oncol. 2016 Nov;62:e3-e4. doi: 10.1016/j.oraloncology.2016.08.007. Epub 2016 Aug 28. No abstract available.

PMID:
27578499
17.

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, Mitchell DC, Bryan BA, Gapihan G, Janin A, Bousquet G, Riveiro ME, Bieche I, Faivre S, Raymond E, de Gramont A.

Oncotarget. 2016 Jun 21;7(25):38467-86. doi: 10.18632/oncotarget.9542.

18.

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.

Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, André T, Chibaudel B, Faivre S.

Acta Oncol. 2016 Sep - Oct;55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670. Epub 2016 Jun 22.

PMID:
27333436
19.

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.

Szturz P, Raymond E, Faivre S.

Oral Oncol. 2016 Aug;59:e12-e14. doi: 10.1016/j.oraloncology.2016.05.017. Epub 2016 Jun 11. No abstract available.

PMID:
27302885
20.

Solar pacing of storm surges, coastal flooding and agricultural losses in the Central Mediterranean.

Kaniewski D, Marriner N, Morhange C, Faivre S, Otto T, Van Campo E.

Sci Rep. 2016 Apr 29;6:25197. doi: 10.1038/srep25197.

21.

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Faivre S, de Gramont A, Raymond E.

Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8. No abstract available.

PMID:
26996978
22.

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.

Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E.

Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16.

PMID:
26377590
23.

Targeting cancer cell metabolism in pancreatic adenocarcinoma.

Cohen R, Neuzillet C, Tijeras-Raballand A, Faivre S, de Gramont A, Raymond E.

Oncotarget. 2015 Jul 10;6(19):16832-47. Review.

24.

[Advanced hepatocellular carcinoma: importance of clinical trials].

Aedo V, Cristina V, Raymond E, Faivre S.

Rev Med Suisse. 2015 May 20;11(475):1149-51. Review. French.

PMID:
26152091
25.

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A.

Oncotarget. 2015 Aug 28;6(25):21614-27.

26.

Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S.

World J Hepatol. 2015 Apr 28;7(6):910-5. doi: 10.4254/wjh.v7.i6.910.

27.

Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours.

Raymond E, Faivre S.

Curr Oncol. 2014 Dec;21(6):309-17. doi: 10.3747/co.21.1647. Review.

28.

Targeting the TGFβ pathway for cancer therapy.

Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A.

Pharmacol Ther. 2015 Mar;147:22-31. doi: 10.1016/j.pharmthera.2014.11.001. Epub 2014 Nov 6. Review.

29.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.

Dos Santos C, Tijeras-Raballand A, Serova M, Sebbagh S, Slimane K, Faivre S, de Gramont A, Raymond E.

Br J Cancer. 2015 Jan 6;112(1):86-94. doi: 10.1038/bjc.2014.578. Epub 2014 Nov 25.

30.

Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.

Valle JW, Faivre S, Hubner RA, Grande E, Raymond E.

Cancer Treat Rev. 2014 Dec;40(10):1230-8. doi: 10.1016/j.ctrv.2014.09.001. Epub 2014 Sep 16.

31.

Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.

Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E.

Am J Transl Res. 2014 Jul 18;6(4):340-52. eCollection 2014. Review.

32.

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S, Raymond E.

Eur J Cancer. 2014 Sep;50(14):2463-77. doi: 10.1016/j.ejca.2014.06.015. Epub 2014 Jul 16.

PMID:
25042151
33.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators.

Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

PMID:
24852116
34.

Benzofuran derivatives as anticancer inhibitors of mTOR signaling.

Salomé C, Ribeiro N, Chavagnan T, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L.

Eur J Med Chem. 2014 Jun 23;81:181-91. doi: 10.1016/j.ejmech.2014.05.014. Epub 2014 May 5.

PMID:
24836070
35.

Cancer wars: natural products strike back.

Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry LG.

Front Chem. 2014 May 1;2:20. doi: 10.3389/fchem.2014.00020. eCollection 2014. Review.

36.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.

Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V.

Invest New Drugs. 2014 Oct;32(5):1028-35. doi: 10.1007/s10637-014-0100-y. Epub 2014 Apr 22.

PMID:
24748335
37.

Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapy.

Pommier R, Ronot M, Cauchy F, Gaujoux S, Fuks D, Faivre S, Belghiti J, Vilgrain V.

Ann Surg Oncol. 2014 Sep;21(9):3077-83. doi: 10.1245/s10434-014-3700-z. Epub 2014 Apr 18.

PMID:
24743912
38.

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.

Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20.

39.

Methods for adjusting for bias due to crossover in oncology trials.

Ishak KJ, Proskorovsky I, Korytowsky B, Sandin R, Faivre S, Valle J.

Pharmacoeconomics. 2014 Jun;32(6):533-46. doi: 10.1007/s40273-014-0145-y.

PMID:
24595585
40.

Pancreatic NETs: where do we stand now?

Faivre S, Castellano D, Strosberg J, González E, Salazar R.

Cancer Metastasis Rev. 2014 Mar;33(1):361-6. doi: 10.1007/s10555-013-9466-0. Review.

PMID:
24452757
41.

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.

Salomé C, Narbonne V, Ribeiro N, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L.

Eur J Med Chem. 2014 Mar 3;74:41-9. doi: 10.1016/j.ejmech.2013.12.020. Epub 2014 Jan 2.

PMID:
24445311
42.

Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.

Malouf GG, Job S, Paradis V, Fabre M, Brugières L, Saintigny P, Vescovo L, Belghiti J, Branchereau S, Faivre S, de Reyniès A, Raymond E.

Hepatology. 2014 Jun;59(6):2228-37. doi: 10.1002/hep.27018. Epub 2014 Apr 30.

PMID:
24443104
43.

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.

Goldwasser F, Faivre S, Alexandre J, Coronado C, Fernández-García EM, Kahatt CM, Paramio PG, Dios JL, Miguel-Lillo B, Raymond E.

Invest New Drugs. 2014 Jun;32(3):500-9. doi: 10.1007/s10637-013-0060-7. Epub 2014 Jan 7.

PMID:
24395456
44.

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.

Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E.

Oncotarget. 2014 Jan 15;5(1):78-94. Review.

45.

MEK in cancer and cancer therapy.

Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E.

Pharmacol Ther. 2014 Feb;141(2):160-71. doi: 10.1016/j.pharmthera.2013.10.001. Epub 2013 Oct 9. Review.

PMID:
24121058
46.

Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.

Bousquet G, Varna M, Ferreira I, Wang L, Mongiat-Artus P, Leboeuf C, de Bazelaire C, Faivre S, Bertheau P, Raymond E, Germain S, Janin A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1183-93. doi: 10.1007/s00280-013-2300-0. Epub 2013 Sep 24.

PMID:
24061866
47.

Unraveling galectin-1 as a novel therapeutic target for cancer.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S.

Cancer Treat Rev. 2014 Mar;40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007. Epub 2013 Aug 1. Review.

PMID:
23953240
48.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators.

Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.

PMID:
23746666
49.

Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.

Barbier L, Fuks D, Pessaux P, Muscari F, Le Treut YP, Faivre S, Belghiti J.

Ann Surg Oncol. 2013 Oct;20(11):3603-9. doi: 10.1245/s10434-013-3029-z. Epub 2013 May 29.

PMID:
23715965
50.

Stromal expression of SPARC in pancreatic adenocarcinoma.

Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E.

Cancer Metastasis Rev. 2013 Dec;32(3-4):585-602. doi: 10.1007/s10555-013-9439-3. Review.

PMID:
23690170

Supplemental Content

Loading ...
Support Center